Cargando…
Discovery of a Non-Nucleoside SETD2 Methyltransferase Inhibitor against Acute Myeloid Leukemia
Histone methyltransferases (HMTs) have attracted considerable attention as potential targets for pharmaceutical intervention in various malignant diseases. These enzymes are known for introducing methyl marks at specific locations of histone proteins, creating a complex system that regulates epigene...
Autores principales: | Bajusz, Dávid, Bognár, Zsolt, Ebner, Jessica, Grebien, Florian, Keserű, György M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471172/ https://www.ncbi.nlm.nih.gov/pubmed/34576219 http://dx.doi.org/10.3390/ijms221810055 |
Ejemplares similares
-
Roles of SETD2 in Leukemia—Transcription, DNA-Damage, and Beyond
por: Skucha, Anna, et al.
Publicado: (2019) -
Discovery of a Selective,
Substrate-Competitive Inhibitor
of the Lysine Methyltransferase SETD8
por: Ma, Anqi, et al.
Publicado: (2014) -
Discovery of a First-in-Class Inhibitor of the Histone
Methyltransferase SETD2 Suitable for Preclinical Studies
por: Lampe, John W., et al.
Publicado: (2021) -
Sequence specificity analysis of the SETD2 protein lysine methyltransferase and discovery of a SETD2 super-substrate
por: Schuhmacher, Maren Kirstin, et al.
Publicado: (2020) -
Discovery of Immunoproteasome Inhibitors Using Large-Scale Covalent Virtual Screening
por: Scarpino, Andrea, et al.
Publicado: (2019)